As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by robust financial health and strategic positioning within their industries.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
Dingdong (Cayman) (DDL)	$2.61	$559.34M	✅ 4 ⚠️ 1 View Analysis >
Waterdrop (WDH)	$1.79	$647.38M	✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS)	$0.825	$141.09M	✅ 4 ⚠️ 1 View Analysis >
LexinFintech Holdings (LX)	$3.00	$504.79M	✅ 4 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.25	$1.36B	✅ 4 ⚠️ 1 View Analysis >
CI&T (CINT)	$4.73	$614.03M	✅ 5 ⚠️ 0 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 1 ⚠️ 5 View Analysis >
Cricut (CRCT)	$4.31	$912.62M	✅ 2 ⚠️ 2 View Analysis >
BAB (BABB)	$0.91	$6.61M	✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT)	$3.90	$88.36M	✅ 3 ⚠️ 2 View Analysis >

Let's review some notable picks from our screened stocks.

ATA Creativity Global (AACG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: ATA Creativity Global, along with its subsidiaries, offers educational services both in China and internationally, with a market cap of $36.84 million.

Operations: The company's revenue segments include CN¥256.91 million from Segment Adjustment and CN¥22.99 million from Other Educational Services.

Market Cap: $36.84M

ATA Creativity Global, with a market cap of $36.84 million, has shown improvement in its financials despite being unprofitable. The company reduced its net loss significantly over the past year and reported a net income of CN¥2.37 million for Q3 2025, compared to a net loss previously. Its short-term assets exceed long-term liabilities but fall short against short-term liabilities, highlighting potential liquidity concerns. Recent efforts to raise $8.85 million through equity offerings suggest ongoing capital needs. While the management and board are seasoned, the stock remains highly volatile with decreased weekly volatility from 18% to 12%.

Aldeyra Therapeutics (ALDX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $278.55 million.

Operations: Aldeyra Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $278.55M

Aldeyra Therapeutics, with a market cap of US$278.55 million, is pre-revenue and remains unprofitable, yet it has managed to reduce its losses over the past five years. The company recently faced an FDA extension for its reproxalap NDA due to additional data requests but received no major deficiencies from the agency. Aldeyra's cash position exceeds its total debt, providing a sufficient runway for operations beyond a year. Despite high share price volatility and negative return on equity, Aldeyra's seasoned management and board offer stability as it pursues advancements in immune-mediated therapies.

MediciNova (MNOV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $78.63 million.

Operations: MediciNova, Inc. does not report any revenue segments.

Market Cap: $78.63M

MediciNova, with a market cap of US$78.63 million, is pre-revenue and unprofitable but has reduced losses over the past five years. The company recently completed patient enrollment for its Phase 2 OXTOX study and Phase 2b/3 COMBAT-ALS trial, both utilizing MN-166 (ibudilast), which has Orphan Drug Designation from the FDA and EMA. Despite high share price volatility, MediciNova's seasoned management team provides stability as it advances its pipeline in neurodegenerative diseases. A recent follow-on equity offering of US$50 million aims to bolster financial resources amid ongoing clinical developments.

Taking Advantage

• Embark on your investment journey to our 334 US Penny Stocks selection here.
• Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.